Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

TB treatment news

Show

From To
NICE publishes new guideline to better tackle tuberculosis

NICE – the National Institute for Health and Care Excellence of England – published guidance on how to better treat and prevent tuberculosis. England has more TB cases than any other country in Western Europe.

Published
15 January 2016
From
NICE press release
MDR-TB treatment: Six drugs better than five

A regimen containing six drugs was more likely to cure multi-drug resistant tuberculosis (MDR-TB) than a regimen containing five drugs, a nine-country observational study has

Published
13 January 2016
By
Keith Alcorn
Xpert MTB/RIF testing has reduced MDR-TB treatment delays in South Africa

Although the introduction of the Xpert MTB/RIF test for TB and drug-resistant TB has improved the time from clinic presentation to second-line treatment in South Africa since

Published
07 January 2016
By
Lesley Odendal
WHO Sounds Alarm Over Big Indian Supplier Of Tuberculosis Drugs

A major Indian supplier of tuberculosis drugs to developing countries has been severely criticized by the World Health Organization for inadequate manufacturing standards and poor testing procedures. The United Nations agency issued a warning letter to Mumbai-based Svizera Labs, part of Maneesh Pharmaceuticals, stating that the approval and use of its products would be suspended if "critical and major observations are not corrected within a reasonable time frame".

Published
15 September 2015
From
Medical Daily
TAG Pipeline Report

2015 report on the pipeline for new HIV, HCV and TB drugs.

Published
17 July 2015
From
TAG
High-dose rifampicin may shorten time to TB clearance

A combination regimen containing high-dose rifampicin (also known as rifampin) was associated with faster tuberculosis (TB) bacteria culture conversion in people with drug-sensitive TB, but moxifloxacin and

Published
13 April 2015
By
Liz Highleyman
Ukraine: Concurrent treatment for HIV/TB co-infection breaks up “deadly alliance”

USAID funded MEASURE Evaluation to initiate an impact evaluation in Ukraine for two TB programmatic priorities: Improving integration of TB and HIV services to reduce mortality through early diagnosis and treatment for co-infected patients; and providing social support services to improve TB treatment adherence.

Published
30 March 2015
From
Science Speaks
Final fight pays off, XXDR-TB & HIV patient cured

Once an active case of extremely drug resistant (XXDR-TB) strain of tuberculosis or totally drug resistant (TDR) TB, 40-year-old Rashid Khan (name changed), has now been completely cured of his disease. Despite having total drug resistance and HIV infection, Khan got cured a few days ago. At one stage he was receiving a cocktail of 18–20 drugs between his HIV and TB regimes. But Bedaquiline made a huge difference in his treatment. He is off medicine now.

Published
24 March 2015
From
DNAIndia
Lancet: Phase 2b trial results of novel TB regimen show potential to shorten treatment

A new tuberculosis (TB) drug regimen designed to improve options for TB therapy eliminated more bacteria from sputum than standard therapy, worked for people with multi-drug-resistant (MDR) TB, and did so in a quarter of the time, according to data from a phase 2b clinical trial published today in The Lancet. These results are published just as the global phase 3 clinical trial, STAND, designed to bring this regimen through the last stage of testing, has begun. The PaMZ regimen uses pretomanid, a new drug; moxifloxacin, an established antibiotic that is experimental as a TB treatment; and pyrazinamide, an established TB drug. Twenty percent of the TB patients enrolled in NC-002 also were co-infected with HIV and the PaMZ regimen appeared to be effective independent of HIV status. See also http://www.aidsmap.com/Novel-TB-regimen-could-reduce-treatment-duration/page/2892700/

Published
18 March 2015
From
Lancet (free registration required)
TB drug candidate starts Phase 1 trial — first in six years

The enrollment of nearly 50 volunteers in the United States will launch the first randomized clinical trial of a potential  new drug to treat TB in six years, the nonprofit product development partnership TB Alliance announced Wednesday.

Published
20 February 2015
From
Science Speaks
← First12345...14Next →

Filter by country